Esperion Therapeutics (ESPR) Tops Q3 EPS by 37c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update
November 2, 2020 4:01 PM EST Quarter-over-quarter Script Growth Exceeded 500 Percent for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) tablets
 U.S. Product Revenue Increased Five-fold During the Third Quarter
 ESPERION Partner Daiichi Sankyo Europe Launches NILEMDO (bempedoic acid) and NUSTENDI (bempedoic acid and ezetimibe) in Germany, the Largest European Market
Conference Call and Webcast today, November 2nd at 4:30 P.M. Eastern Time
ANN ARBOR, Mich., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ESPERION (NASDAQ: ESPR) today reported financial results for the third quarter ended September 30, 2020, and... More
